Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

NCT07240844 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Amyloid Cardiomyopathy

Interventions

DRUG: Enavogliflozin 0.3mg
DRUG: Placebo

Sponsor

Seoul St. Mary's Hospital

Collaborators

[object Object]